排序方式: 共有198条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
15.
16.
17.
《Best Practice & Research: Clinical Haematology》2023,36(1):101449
Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin Lymphoma (NHL) in children, adolescents, and young adults (CAYA), accounting for 25–35% of all cases. T-lymphoblastic lymphoma (T-LBL) comprises 70–80% of cases, while precursor B-lymphoblastic lymphoma (pB-LBL) makes up the remaining 20–25% of cases. Event-free and overall survival (EFS and OS) for paediatric LBL patients both exceed 80% with current therapies. Treatment regimens, especially in T-LBL with large mediastinal tumours, are complex with significant toxicity and long-term complications. Though prognosis overall is good for T-LBL and pB-LBL with upfront therapy, outcomes for patients with relapsed or refractory (r/r) disease remain dismal. Here, we review new understanding about the pathogenesis and biology of LBL, recent clinical results and future directions for therapy, and remaining obstacles to improve outcomes while reducing toxicity. 相似文献
18.
卵巢癌是最致命的妇科肿瘤,由于其发病潜伏期长,缺乏早期诊断手段,导致大多数患者初治时已是晚期。除了常规的手术化疗外,近年来,嵌合抗原受体修饰的T细胞(CAR-T)在肿瘤系统治疗的研究领域中受到相当大的关注。各种临床前实验和临床试验已证实了CAR-T细胞免疫疗法是卵巢癌的一种有前景的治疗方法,并显示出有别于其他实体瘤的优势,但是仍需要面对诸多挑战。在这篇综述中,我们将系统的讲述CAR-T细胞免疫疗法的最新研究进展,包括CAR-T细胞疗法的生物学理解、临床应用、所面对的挑战及可能改善治疗效果的策略。 相似文献
19.
20.